Bluebird Bio price target lowered to $5 from $40 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...
pharmaphorum23m
Pfizer drops Beqvez, leaving gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Here's Why AST SpaceMobile Stock Is a Buy Before March 3
AST SpaceMobile (NASDAQ: ASTS), a producer of low earth orbit (LEO) satellites for cellular networks, saw its stock soar more ...
Atmus Filtration price target lowered to $39 from $40 at Wells Fargo
Wells Fargo analyst Joseph O’Dea lowered the firm’s price target on Atmus Filtration (ATMU) to $39 from $40 on Friday and keeps an Equal Weight ...